X
<

How Novartis Fared in 4Q17

PART:
1 2 3 4 5 6 7 8
Part 2
How Novartis Fared in 4Q17 PART 2 OF 8

How Novartis’s Revenues Trended in 4Q17

Novartis’s revenues in 4Q17

Novartis (NVS) reported 5% growth in revenues to ~$12.9 billion during 4Q17 as compared to ~$12.3 billion during 4Q16. The below chart compares revenues for Novartis since 1Q16.

How Novartis’s Revenues Trended in 4Q17

Interested in NVS? Don't miss the next report.

Receive e-mail alerts for new research on NVS

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

4Q17 revenues

Novartis surpassed Wall Street analysts’ estimates for earnings per share (or EPS) with posted EPS of $1.21 as compared to the estimates of $1.19 during 4Q17. Novartis also surpassed analysts’ estimates for revenues with reported revenues of ~$12.9 billion as compared to the estimates of ~$12.8 billion during 4Q17. The revenues increased by ~5% including a 2% growth in operating revenues and a 3% favorable impact of foreign exchange during 4Q17.

The US sales reported a 1% decline to ~$4.3 billion during 4Q17 as compared to ~$4.4 billion during 4Q16. European markets saw an 8% increase in sales to ~$4.7 billion during 4Q17, as compared to ~$4.3 billion during 4Q16. The Canada and Latin America markets saw a 7% increase in sales to ~$1.0 billion during 4Q17, as compared to $963 million during 4Q16. The Asia/Africa/Australasia markets saw a ~8% increase in sales to ~$2.9 billion during 4Q17 as compared to ~$2.6 billion during 4Q16.

2017 revenues

Novartis surpassed Wall Street analysts’ estimates for earnings per share (or EPS) with reported EPS of $4.86 as compared to estimates of $4.82 for 2017. However, Novartis missed the revenue estimates for 2017 and reported revenues of ~$49.1 billion as compared to the estimates of ~$49.2 billion during 2017. The revenues increased by ~1% during 2017, including a 2% growth in operating revenues, offset by a ~1% negative impact of foreign exchange.

The US sales reported a 1% decline to ~$16.9 billion during 2017 as compared to ~$17.1 billion during 2016. European markets saw a 2% growth in revenues to ~$17.5 billion during 2017 as compared to ~$17.1 billion during 2016. Sales from Canada and Latin America markets reported 2% growth to ~$4.0 billion during 2017 as compared to $3.9 billion during 2016. The Asia/Africa/Australasia markets reported a ~3% increase in sales to ~$10.7 billion during 2017 as compared to ~$10.4 billion during 2016.

The First Trust Value Line Dividend ETF (FVD) holds 6.3% of its total investments in healthcare companies. FVD holds 0.5% in Novartis (NVS), 0.5% in GlaxoSmithKline (GSK), 0.5% in Merck (MRK), and 0.5% in Bristol-Myers Squibb (BMY).

X

Please select a profession that best describes you: